Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
Savani, R
These pathways play a crucial role in its wide-ranging therapeutic effects, extending the benefits of GLP-1RAs beyond metabolic diseases
In a phase I clinical trial, the safety, tolerance, and pharmacokinetic effects of bremelanotide were assessed in both male and female participants
To view the Addenda to this final rule with comment period pertaining to CY 2026 payments under the OPPS, we refer readers to the CMS website at
These clinical trials evaluated PT-141s safety profile, dosing thresholds, and treatment-emergent adverse events across diverse populations, including premenopausal women with hypoactive sexual disorder